COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry - UAE
Written By
Partner
United Arab Emirates
I am the head of the Intellectual Property Group for the Middle East offices and a partner in the International Commercial Group. I've practised in the UAE since 2006 and I'm ranked in IP Stars, Chambers & Partners, Legal 500 and Who's Who Legal for my commercial and intellectual property experience.
Partner
United Arab Emirates
I'm a partner in our Corporate Group, based in the UAE, where I work as a lead counsel in M&A transactions. I also specialise in provision of employment law solutions to our clients.
Related
Sectors
Trending Topics
Countries
Partner, Melissa Murray and Senior Associate, Surabhi Singhi provided content for the United Arab Emirates.
COVID-19 presents an unprecedented challenge to the global life sciences industry. Members of Bird & Bird's International Life Sciences & Healthcare team, lawyers who have a wealth of hands-on experience and strong relationships with regulatory bodies, have worked together to provide an update in the form of a Q&A for each of the countries we are located. This update aims to provide guidance on the responses of EU, Asia-Pac and UAE regulators in the areas of clinical trials, medical devices, market access, public procurement and compulsory licensing.
Latest insights
More Insights
Quantum technologies and quantum computing in life sciences: transformative potential and legal challenges
9 minutes Apr 28 2025
Gen AI at work: Hong Kong Privacy Commissioner publishes further AI guidance on the use of Gen AI by employees
Apr 03 2025
Applications for provisional measures before the UPC – what may be granted?
5 minutes Mar 31 2025